A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Inclusion Criteria:
Aged ≥ 18 years.
Clinical diagnosis of nonsegmental vitiligo and meet the following:
Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Birmingham, Alabama 35294-0007, United States
Los Angeles, California 90036-5609, United States
Indianapolis, Indiana 46202-3082, United States
Sofia, 01407, Bulgaria
Vancouver, British Columbia V5Z 4E8, Canada
Wrocaw, 03-291, Poland